# EDGAR Filing Document

**Accession Number:** 0001642159
**File Stem:** 0001641172-25-024221
**Filing Date:** 2025-8
**Character Count:** 6689
**Document Hash:** 8f5f9dd452190185b5a07f9a06ba41db
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-024221.hdr.sgml**: 20250815

**ACCESSION NUMBER**: 0001641172-25-024221

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250815

**DATE AS OF CHANGE**: 20250814

**EFFECTIVENESS DATE**: 20250815

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sigyn Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001642159
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472573116
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-55575
- **FILM NUMBER:** 251221647

**BUSINESS ADDRESS:**
- **STREET 1:** 9190 W OLYMPIC BLVD # 263
- **CITY:** BEVERLY HILLS
- **STATE:** CA
- **ZIP:** 90212
- **BUSINESS PHONE:** 619-368-2000

**MAIL ADDRESS:**
- **STREET 1:** 9190 W OLYMPIC BLVD # 263
- **CITY:** BEVERLY HILLS
- **STATE:** CA
- **ZIP:** 90212

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reign Resources Corp
- **DATE OF NAME CHANGE:** 20200512

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reign Sapphire Corp
- **DATE OF NAME CHANGE:** 20150512

---

| | | |
|:---|:---|:---|
|  | OMB APPROVAL | OMB APPROVAL |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** | OMB Number: | 3235-0058 |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** | Expires: | April 30, 2025 |
| **UNITED STATES**<br> **SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549** | Estimated average burden hours per response 2.50 | Estimated average burden hours per response 2.50 |
| **FORM 12b-25** | SEC FILE NUMBER | SEC FILE NUMBER |
| **FORM 12b-25** |  |  |
|  | CUSIP NUMBER | CUSIP NUMBER |
| **NOTIFICATION OF LATE FILING** |  |  |

---

*(Check one):* ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K <br> ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

For Period Ended: June 30, 2025

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended:____________________________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

**Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

Sigyn Therapeutics, Inc**.**

Full Name of Registrant

------

Former Name if Applicable

2305 Historic Decatur Road, Suite 100

Address of Principal Executive Office (Street and Number)

San Diego, California 92106

City, State and Zip Code

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

&nbsp;&nbsp;&nbsp;&nbsp;(a) The
 reason described in reasonable detail in Part III of this Form could not be eliminated without
 unreasonable effort or expense;

☒ (b) The subject annual report, semi-annual
report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before
the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject
distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due
date; and

(c) The
 accountant's statement or other exhibit required by Rule 12b-25(c) has been attached
 if applicable.

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the Form 10-Q has imposed time constraints that have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant. The registrant undertakes the responsibility to file such quarterly report no later than five days after its original due date.

**PART IV — OTHER INFORMATION**

&nbsp;&nbsp;&nbsp;&nbsp;(1) Name
 and telephone number of person to contact in regard to this notification

<u>James Joyce</u> <u>619</u> <u>353-0800</u> <br> (Name) (Area Code) (Telephone Number)

&nbsp;&nbsp;&nbsp;&nbsp;(2) Have
 all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
 Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such
 report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐
 No

&nbsp;&nbsp;&nbsp;&nbsp;(3) Is
 it anticipated that any significant change in results of operations from the corresponding
 period for the last fiscal year will be reflected by the earnings statements to be included
 in the subject report or portion thereof?

☐ Yes ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2 of 3

**SIGYN THERAPEUTICS, INC.**

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | August 14, 2025 | By: | */s/ James Joyce* |
|  |  | Name: | James Joyce |
|  |  | Title: | Chief Executive Officer |

---

INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the Form.

---

| | |
|:---|:---|
| | ATTENTION |
|  | ATTENTION |
| **Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).** | **Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).** |

---

3 of 3